PODD - インスレット (Insulet Corporation)


   Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2022 Results - Earnings Call Transcript  2022/05/06 21:23:07 Seeking Alpha
Insulet Corporation (NASDAQ:NASDAQ:PODD) Q1 2022 Earnings Conference Call May 05, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Shacey Petrovic -…
   Insulet -11% after Wells Fargo lowers PT after Q1 earnings  2022/05/06 17:56:21 Seeking Alpha
Insulet (PODD) falls 11% after Wells Fargo analyst cuts PT to $345 from $357.The company''s Q1 earnings topped expectations and announced CEO transition.
   Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is ''Progressing Very Well''  2022/05/06 13:55:52 Benzinga
Insulet Corporation (NASDAQ: PODD ) posted Q1 profits of $27.8 million , or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off to a great start … Full story available on Benzinga.com
   May 5, 2022 4:30 PM EDT : Q1 2022 Insulet Corporation Earnings Conference Call  2022/05/05 20:30:00 Investor Insulet
The Investor Relations website contains information about Insulet Corporation''s business for stockholders, potential investors, and financial analysts.
   Insulet CEO Shacey Petrovic to step down  2022/05/05 20:26:30 Seeking Alpha
Insulet (PODD) said Thursday Shacey Petrovic will step down from her role as president and CEO for personal reasons, effective Jun. 1.Petrovic will continue to serve on PODD''s board
   Insulet Corporation (PODD) Could Be Possessing A Gold Mine  2022/02/26 12:30:00 Stocks Register
Insulet Corporation (NASDAQ:PODD) concluded the trading at $262.37 on Friday, February 25 with a rise of 2.74% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $255.37 and 5Y monthly beta was reading 0.70 with its price kept floating in the range … Insulet Corporation (PODD) Could Be Possessing A Gold Mine Read More »
   Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%  2022/02/24 11:41:07 Benzinga
Insulet Corp''s (NASDAQ: PODD ) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million , exceeding the consensus of $301.06 million. The company brought in $275.8 million in revenues for its Omnipod insulin delivery platform for the quarter, representing a 19.3% increase. Insulet posted Q4 EPS of $0.42, a shift from EPS loss of $(0.26) a year … Full story available on Benzinga.com
   Insulet Corporation (PODD) CEO Shacey Petrovic On Q4 2021 Results - Earnings Call Transcript  2022/02/24 01:45:25 Seeking Alpha
   Insulet GAAP EPS of $0.42 beats by $0.11, revenue of $307.7M beats by $7.13M (NASDAQ:PODD)  2022/02/23 21:04:13 Seeking Alpha
Insulet press release (PODD): Q4 GAAP EPS of $0.42 beats by $0.11.Revenue of $307.7M (+25.0% Y/Y) beats by $7.13M.Gross margin of 69.3%, up 380 basis points.Adjusted EBITDA of…
   Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year  2022/02/23 21:01:00 Business Wire
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2021. Full Year Financial Highlights: Full Year 2021 revenue of $1.1 billion, up 21.5%, or 19.7% in constant currency1, compared to $904.4 million in the prior year, at the high-end of the guidance range of 18% to 20% in constan
   Insulet upgraded at Oppenheimer despite recent surge on FDA approval for Omnipod 5  2022/01/31 16:46:39 Seeking Alpha
Following more than 18% rise on Friday in reaction to its announcement on the FDA approval of Omnipod 5, Insulet <> is extending gains after Oppenheimer upgraded the stock
   FDA clears Insulet''s Omnipod 5 automated insulin delivery system  2022/01/28 11:32:16 Seeking Alpha
Insulet (PODD) has received clearance from the FDA for its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged six years and older with type 1 diabetes
   Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control  2022/01/28 11:00:00 Kwhen Finance
   CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022  2022/01/12 15:16:00 Kwhen Finance
   Private Advisor Group LLC Sells 200 Shares of Insulet Co. (NASDAQ:PODD)  2021/12/13 09:54:41 Dakota Financial News
Private Advisor Group LLC cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 10.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,700 shares of the medical instruments suppliers stock after selling 200 shares during the period. Private []